Corbus Taps Oncology Veteran as CMO Ahead of Key Clinical Milestones
Event summary
- Corbus Pharmaceuticals appointed Leonardo Viana Nicacio, M.D., as Chief Medical Officer effective July 6, 2026.
- Dr. Nicacio brings over 20 years of experience in oncology drug development, including pivotal roles at Seagen and AstraZeneca.
- Corbus plans to initiate the TEMPO-1 registrational study for CRB-701 in 2L OPSCC this summer.
- Topline data from the CANYON-1 obesity study of CRB-913 is expected in late summer 2026.
The big picture
Corbus' appointment of Dr. Nicacio underscores its strategic focus on advancing two high-potential drug candidates in oncology and obesity. The move comes as the company prepares for multiple near-term clinical milestones, positioning it to compete in rapidly evolving therapeutic areas. Dr. Nicacio's extensive experience in ADC development and regulatory strategy could be pivotal in navigating Corbus through these critical phases.
What we're watching
- Clinical Execution
- Whether Corbus can successfully initiate and execute the TEMPO-1 study for CRB-701 in OPSCC as planned this summer.
- Regulatory Alignment
- The pace at which FDA alignment on trial designs translates into accelerated approval pathways for CRB-701.
- Pipeline Momentum
- How Dr. Nicacio's leadership impacts the advancement of both CRB-701 and CRB-913 through critical clinical milestones.